Needham Maintains Buy on Collegium Pharmaceutical, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has maintained a Buy rating on Collegium Pharmaceutical (NASDAQ:COLL) and increased the price target from $36 to $40.
January 04, 2024 | 5:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst reaffirms Buy rating on Collegium Pharmaceutical and raises price target to $40, indicating a positive outlook.
The increase in price target by a reputable analyst typically signals a positive outlook on the company's future performance and can lead to increased investor confidence, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100